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(Cancer Cell 27, 780–796; June 8, 2015)
The Experimental Procedures of this article contained an error related to the source of key reagents. In the first paragraph on page
795, line 7, the source for antibodies MF-1 and DC101 was wrongly cited as ‘‘ImClone Systems.’’
The corrected sentence follows here: ‘‘Different cohorts of mice treated with MF-1 (Eli Lilly and Company), DC101 (Eli Lilly and
Company), or control IgG (DivBioScience) were injected systemically (each 40 mg/kg body weight) every third day over 4 weeks
post-tumor implantation (Carmeliet et al., 2001; Fischer et al., 2007).’’
Furthermore, the authors would like to add the following sentence to the Acknowledgments section: ‘‘The authors gratefully acknowl-
edge the generous gift of proprietary antibodies (MF-1 and DC101) by Eli Lilly and Company.’’
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